aurinia pharmaceuticals appoints charlie rowland to its board of directors and audit committee email protected twitterlinkedin about our vision our mission our team our values our partners faq terms  conditions privacy policy board news latest board news board news by location… europe usa  canada middle east all the others board news by company type public  listed vc  pe backed privately held trust  fund  reit board news by industry… life sciences  health care financials information technology women on board submit a press release board directory company press releases public  listed global  fortune  private or vc  pe backed unicorns trust  fund newsletter contact log in register select pageabout    our vision our mission     our team     our values     our partners     faq     terms  conditions     privacy policy board news    latest board news     board news by location…        europe         usa  canada         middle east         all the others     board news by company type        public  listed         vc  pe backed         privately held         trust  fund  reit     board news by industry…        life sciences  health care         financials         information technology     women on board     submit a press release board directory    company press releases     public  listed     global      fortune      private or vc  pe backed     unicorns     trust  fund newsletter contact log in register homeboard  usa  can board listedpublic companies aurinia pharmaceuticals appoints charlie rowland to its board of directors and audit committee aurinia pharmaceuticals appoints charlie rowland to its board of directors and audit committee july   by talentboards team comments are off board  usa  can board listedpublic companies – canada bc – aurinia pharmaceuticals inc aupto today announced that mr charles rowland jr has joined its board of directors and will assume the role of audit committee chair mr rowland has over  years of diversified financial experience most recently mr rowland was vice president and chief financial officer of viropharma inc which was acquired in january of  by shire plc for over  billion he has also served as interim coceo and cfo at endo pharmaceuticals inc and cfo at biovail pharmaceuticals corporation acquired by valeant pharmaceuticals international inc mr rowland is a cpa and holds an mba from rutger’s university and a bs in accounting from saint joseph’s university “the company is pleased to welcome mr rowland to our board as he brings a high level of financial expertise and a breadth of experience within our business sector” said mr stephen zaruby aurinia’s president and chief executive officer “his addition to the board will provide greater financial oversight and board independence for our company” the company has filed an application to list its shares on the nasdaq global market upon meeting the required listing criteria the company expects to begin trading on this exchange shortly thereafter “mr rowland’s extensive financial experience and his cpa designation qualifies him to act as an audit committee chair as per the nasdaq requirements therefore his appointment to our board is an important step in our preparations towards an anticipated nasdaq listing” said stephen zaruby in conjunction with mr rowland joining the board mr michael martin chief operating officer of the company and cofounder of aurinia pharma corp has agreed to step off the board “the company would like to thank mr martin for his gracious offer to step off the board so that mr rowland could be appointed mr martin will continue to play a critical role as chief operating officer” said dr richard glickman the company’s chairman of the board about aurinia aurinia is a clinical stage pharmaceutical company focused on the global nephrology market it is currently enrolling patients in its phase b clinical trial to evaluate the efficacy of its drug voclosporin as a treatment for lupus nephritis “ln” ln is an inflammation of the kidneys that if inadequately treated can lead to endstage renal disease making ln a serious and potentially lifethreatening condition voclosporin is a novel and potentially best in class calcineurin inhibitor “cni” with extensive clinical data in over  patients in other indications voclosporin is made by a modification of a single amino acid of the cyclosporine molecule a cni approved for use in transplant patients since  this modification results in a more predictable pharmacokinetic and pharmacodynamic relationship an increase in potency vs cyclosporine an altered metabolic profile and potential for flat dosing aurinia also has development and commercialization partners in canada israel south africa and greater china  disclaimer  news data and statement included in this release are intended exclusively for information purposes product and brand names used in this release maybe trademarks or registered trade marks of their respective owners talentboards accepts neither liability for the consequences of the reader’s reliance nor responsibility for the adequacy or accuracy of this release no data or statement in this release should be considered a recommendation for the purchase retention or sale of the securities referred to hereinother related postsaurinia pharmaceuticals appoints charlie rowland to the board of directors as ceoaurinia pharmaceuticals appoints jeff randall to its board of directorsaurinia pharmaceuticals appoints stephen zaruby as president  ceo comments are closed latest boardroom news standard chartered announces dr ngozi okonjoiweala to its board as upcoming independent nonexecutive director july   tristar resources appoints mark wellesleywood as executive chairman july   pacific city financial appoints sang lee as new chairman of the board of directors july   medallion financial adds john everets to its board as independent director july   morgan stanley announces board member tom glocer as upcoming independent lead director july   random boardsmytutorvanaramaliquidsharebooker groupsafestore holdings    talentboards inc  all rights reserved  geneva  miami  london  boston  paris  shanghai  monaco  blueprint medicines appoints charles a rowland jr to its board of directors blueprint medicines appoints charles a rowland jr to its board of directors mar    et from blueprint medicines cambridge mass march   prnewswire  blueprint medicines today announced the appointment of charles a rowland jr cpa to its board of directors mr rowland brings more than  years of experience in biopharmaceutical financial management and strategic business operations with his extensive leadership and financial management experience charlie promises to be a tremendous asset to blueprint as we advance simultaneously our two lead programs into clinical development said jeffrey albers chief executive officer of blueprint medicines charlie has a proven track record of building highvalue companies through strategic investment in research and development and smart financial management mr rowland most recently served as the vice president and chief financial officer cfo of viropharma a global biopharmaceutical company with  million in revenues until the company was acquired by shire plc in january  in this role he oversaw all aspects of finance including financial analysis and reporting tax treasury and investor relations as well as strategic business planning and information technology before joining viropharma in  mr rowland was executive vice president and cfo as well as interim cochief executive officer for endo pharmaceuticals a specialty pharmaceutical company with  billion in revenues he previously held finance positions of increasing responsibility at biovail pharmaceuticals breakaway technologies pharmacia corp novartis ag and bristolmyers squibb co mr rowland also serves as a director and chair of the audit committees of aurinia pharmaceuticals bind therapeutics vitae pharmaceuticals and nabriva therapeutics ag he holds an mba from rutgers university and a bs from saint josephs university i look forward to working with the leadership team and board of blueprint medicines to advance their mission to discover develop and deliver genomically defined medicines to patients in need said mr rowland about blueprint medicines blueprint medicines makes kinase drugs to treat patients with genomically defined diseases led by a team of industry innovators blueprint medicines integrates a novel target discovery engine and a proprietary compound library to understand the blueprint of cancer and craft highly selective therapies this empowers the blueprint medicines team to develop patientdefined medicines aimed at eradicating cancer contact investor relationsbeth delgiaccostern investor relations incbethsternircom media relationsbeth keshishianinventiv health pr   bethkeshishianinventivhealthcom source blueprint medicines related links httpwwwblueprintmedicinescom view table fullscreen view table fullscreen journalists and bloggers the news you need when you need it join pr newswire for journalists to access all of the free services designated to make your job easier in need of subject matter experts for your story submit a free profnet request and find the sources you need learn more mar    et preview blueprint medicines files registration statement for proposed initial public offering mar    et preview blueprint medicines publishes preclinical proofofconcept data on promising new therapy for patients with genomically defined hepatocellular carcinoma my news release contains wide tables view fullscreen read more may    et blueprint medicines to present at upcoming investor conferences may    et blueprint medicines to present new data from ongoing phase  may    et blueprint medicines reports first quarter  financial results looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft charles a rowland jr  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in charles a rowland jr board member at dnib unwind view full profile are you charles a rowland jr claim your profile   sign up for equilar atlas and view charles a rowland jrs full profile with equilar atlas you can identify corporate executives in charles a rowland jrs network and community follow changes in charles a rowland jrs employment and moneyinmotion connect with charles a rowland jr through your network of contacts charles a rowland jrs executive work history current board member dnib unwind past to view charles a rowland jrs complete executive work history sign up now education bs saint josephs university age      charles a rowland jrs biography charles a rowland jr mba has served as a member of our board of directors since march  from april  to february  mr rowland served as president and chief executive officer of aurinia pharmaceuticals inc or aurinia and as a member of the board of directors of aurinia from july  to february  mr rowland previously served as vice president and chief financial officer of viropharma incorporated or viropharma an international biopharmaceutical company from october  until it was acquired by shire plc in january  prior to joining viropharma from  to  mr rowland served as executive vice president a  read more charles a rowland jr mba has served as a member of our board of directors since march  from april  to february  mr rowland served as president and chief executive officer of aurinia pharmaceuticals inc or aurinia and as a member of the board of directors of aurinia from july  to february  mr rowland previously served as vice president and chief financial officer of viropharma incorporated or viropharma an international biopharmaceutical company from october  until it was acquired by shire plc in january  prior to joining viropharma from  to  mr rowland served as executive vice president and chief financial officer as well as the interim cochief executive officer for endo pharmaceuticals inc a specialty pharmaceutical company with a primary focus in pain management mr rowland previously held positions of increasing responsibility at biovail pharmaceuticals inc breakaway technologies inc pharmacia corporation novartis ag and bristolmyers squibb co each a biopharmaceutical company mr rowland joined the board of directors of idenix pharmaceuticals inc a biopharmaceutical company in june  and served as a member of its audit committee until idenix was acquired by merck  co inc in august  mr rowland served as a member of the board of directors and chairman of the audit committee of vitae pharmaceuticals inc from september  until it was acquired by allergan in september  since january  he has served as a member of the supervisory board and chairman of the audit committee of nabriva therapeutics ag a biotechnology company based in vienna austria mr rowland served as a member of the board of directors and chairman of the audit committee of bind therapeutics inc or bind from may  to july  mr rowland received a bs in accounting from saint josephs university and an mba with a finance concentration from rutgers university we believe that mr rowlands extensive professional experience as a chief financial executive in the biotechnology and pharmaceutical industries and his experience serving as a director of various publicly traded biotechnology companies qualifies him to serve as a member of our board of directors source blueprint medicines on    sign up for equilar atlas and view charles a rowland jrs full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like charles a rowland jr more specifically youll be able to identify corporate executives in charles a rowland jrs network and community follow changes in charles a rowland jrs employment and moneyinmotion connect with charles a rowland jr through your network of conections view full profile   search for over  executive profiles bio example charles a rowland jr charles a rowland jrs connections  sign up now to view charles a rowland jrs  connections » george d demetri former board member blueprint medicines daniel d burgess board member arbutus biopharma corporation roger h kimmel chairman of the board endo international plc robert s langer board member dnib unwind jamie c sokalsky board member agnico eagle mines limited michel de rosen former chief executive officer viropharma inc howard h pien board member immunogen inc stephen w webster chief financial officer spark therapeutics inc matthew w foehr president and chief operating officer ligand pharmaceuticals incorporated peter barrett board member perkinelmer inc popular profiles sign up now to view more executive profiles » thomas j lynch executive chairman te connectivity ltd john j kita evp and cfo a o smith carl g annessa evp and coo hornbeck offshore services inc elon r musk ceo and chairman tesla michael c montgomery board member nmi holdings inc × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login ï¿½  equilar all rights reserved privacy policy  marshall street redwood city ca   phone    fax   rowland family history by jordan shoemaker on prezicreateexplorelearn  supportget startedlog inpricingget startedlog inmy prezisexplorelearn  supportproductcompanycareerssupportcommunitycontactappsenglishespañol한국어deutschportuguêsfrançaismagyaritaliano×houston we have a problemoops a firewall is blocking access to prezi content check out this article to learn more or contact your system administrator stand out and be remembered with prezi the secret weapon of great presenters get started today get started what is prezi learn more loading presentation you’re using the new improved player you can always go back to the old viewer switch back public  reusable create your own make a copy share embed liked like present remotely send the link below via email or imcopy present to your audiencestart remote presentationinvited audience members will follow you as you navigate and presentpeople invited to a presentation do not need a prezi accountthis link expires  minutes after you close the presentationa maximum of  users can follow your presentationlearn more about this feature in our knowledge base article do you really want to delete this prezi neither you nor the coeditors you shared it with will be able to recover it again deletecancelmake your likes visible on facebook connect your facebook account to prezi and let your likes appear on your timeline you can change this under settings  account at any time no thanksconnect with facebookrowland family history no description by jordan shoemaker on  april  tweetcomments  please log in to add your comment report abusetranscript of rowland family historyrowland family historythe rowland family emerged in america around  with its first full generation living from the s to the s in samuel rowland sr they were a strong english family arriving in arriving in fairfield connecticut as land ownersthe relevant generations to beechhaven begin with charles alden rowland i  and his wife katherine barnes whitehead rowland familycharles alden rowland jr july  april   married effie elizabeth hampton on may  they had  children hampton katherine whitehead elizabeth leonard alice alden and charles alden iiicharles alden was apparently incredibly short as a child which was attributed to his chess playing he was sent to tennessee to consume limestone water and build up his physique instead of attending the university of georgia it was in tn that he had his faith reaffirmed he returns to athens in  where he works in a print shop and joins the ymcahe and effie meet in the presbyterian church and have their first date on a ride homehe believed that beechhaven would complete his life after his experiences at montreat and the forward movement he refers to it as  a little montreatcharles alden rowland ii and effie elizabeth hamptonborn in athens on may  attends uga officer in the quartermaster corps us army during wwiga lobbyist for seed reformdeacon at first presbyterian president of masonic lodgemarried mary asenith lamb in august  she was a teacher and uga graduate class of they have  children hampton jr and jackmary passes in december hampton remarries on november   to grace emily hancock daughter of alonzo church hancockshe was also an educator in athens and a uga graduatehampton dies on november  hampton rowland srthey were married on june  katherine was of the plantation ivanhoe in burke county ga charles served in the confederate army under joesph e johnston which was believed to have caused his deafness and fought at the battles of chickamauga and atlantahe returned to augusta where he established a wholesale grocery business later a cotton wholesalehe banded with  others to charter augustas second presbyterian church in anecdotes include a love reading practical jokes gardening and confederate veteranskatherines family lived at ivanhoe but used nearby bath as a summer retreatshe kept an extensive diary of the civil warshe also was a strong supporter of foreign missions served as president for the missionary society and inspired her granddaughters to travel as a couple they had  children willian malthie amos whitehead annie mckinne elizabeth whitehead charles alden and clarence leonard charles alden rowland i  and his wife katherine barnes whitehead hampton rowland jr born in athens on october  entered uga at  on a scholarship from the state of georgia member of the kappa alpha fraternity lettered in swimming and member of the glee clubentered the us army in  in the calvary and air corpsstationed in long beach where he met widow betty jane monahan bee hampton adopts her children michaelyn mike and monnette twink have hampton iii together in serves in korea winning a bronze star combat infantrymans badge and commendation medalreturns to uga in night school earning a ma in education attends various officer acadamies serves in the caribbean panama canal zone and later in augusta serves as the executive officer at the us behavorial research laboratory retires in  after  years and awarded the legion of meritearns a ma in educational administration in  at florida state joins the faculty in anthropology jack lamb rowlandborn in cochran while his mother was on vacationattended the university of georgia joined the medical corps during wwii and was stationed in hawaiireturned to athens graduated with a bs in business administration worked with father and grandfather in wholesale feed salesmarried jeffie pearl landers of jacsonville al she received a ma in art from the lamar dodd school of art served as an art supervisor in the clarke co school district active in the first presbyterian church rotary york rite masons and shriner family has always owned walking horses and are active hunterskatherine whitehead rowlandborn in athens on march  attended the lucy cobb institute at a laymans missionary convention in chattanooga tn she met paul sackett crane of yazoo city ms  they married on may   at beechhavenstarted a church in carrollton mson august   they left for mission in koreaon march   paul was killed in a train accident outside seoulkatherine returns home on june   and married her brotherinlaw william earl cranethey served as counseling pastors at nd presbyterian in knoxville tnreturned to athens and lived at willowwynde within the beechhaven complex full transcriptpopular presentationssee more popular or the latest prezispreziproductgallerythe scienceconversational presentingfor businesstestimonialscompanyaboutteamcareersour valuespressour customerscontact uslanguages english español 한국어  deutsch português français magyar italiano infogramchartsinfographicssupportprezi next supportprezi classic supportblogsee all  prezi inc termspreziproductgallerythe scienceconversational presentingfor businesstestimonialsinfograminfogramchartsinfographicscompanyaboutteamcareersour valuespressour customerscontact ussupportprezi next supportprezi classic supportlanguages english español 한국어  deutsch português français magyar italiano   prezi inc termsconnect your facebook account to prezi and publish your likes in the future okno thanks news on charles rowland jr news home advertising board and executive moves energy health care hedge funds m  a private equity technology person charles rowland jr ▼ topic all topics ▼ organizations find news about organizations alumni find news on alumni of any org industries find news on a particular market your contacts find news on your contacts sign up for free daily alerts on this feed by pressing sign up you agree to our terms of use privacy policy and the lexisnexis terms  conditions follow change feed charles rowland jr weekly aurinia pharmaceuticals in its biggest weekly gain in  weeks july    edt july    •  news bites canadian markets  the exercise price is c  shareholder value added by directors charles a rowland was appointed president of aurinia pharmaceuticals tsxaup one year ago on  charles rowland jr is now serving in a new board position at viking therapeutics inc july    •  relsci data update viking therapeutics appoints charles a rowland jr to board of directors july    •  pr newswire  therapies for metabolic and endocrine disorders today announced the appointment of charles a rowland jr to its board of directors with more than  years  weekly aurinia pharmaceuticals in its biggest weekly loss in  month june    edt june    •  news bites canadian markets  the exercise price is c  shareholder value added by directors charles a rowland was appointed president of aurinia pharmaceuticals tsxaup one year ago on  nabriva therapeutics appoints carrie bourdow and colin broom to the board june    •  globenewswire  khuong of orbimed advisors llc george talbot md of talbot advisors llc charles rowland former ceo of aurinia pharmaceuticals and stephen webster cfo of spark  weekly aurinia pharmaceuticals in its biggest weekly gain in  months june    edt june    •  news bites canadian markets  the exercise price is c  shareholder value added by directors charles a rowland was appointed president of aurinia pharmaceuticals tsxaup one year ago on  morning alert aurinia pharmaceuticals climbs  leads biotechnology sector higher  june   edt june    •  news bites canadian markets  buying and selling insider buying and selling aurinia pharmaceuticals tsxaup director charles a rowland bought  shares worth cad on january  the purchase price  weekly aurinia pharmaceuticals down  in  weeks june    edt june    •  news bites canadian markets  the exercise price is c  shareholder value added by directors charles a rowland was appointed president of aurinia pharmaceuticals tsxaup one year ago on  aurinia pharmaceuticals down  in  days june    edt june    •  news bites canadian markets  buying and selling insider buying and selling aurinia pharmaceuticals tsxaup director charles a rowland bought  shares worth cad on january  the purchase price  weekly aurinia pharmaceuticals in its biggest weekly loss in  weeks june    edt june    •  news bites canadian markets  the exercise price is c  shareholder value added by directors charles a rowland was appointed president of aurinia pharmaceuticals tsxaup one year ago on  aurinia pharmaceuticals in its biggest weekly gain in  months june    edt june    •  news bites canadian markets  buying and selling insider buying and selling aurinia pharmaceuticals tsxaup director charles a rowland bought  shares worth cad on january  the purchase price  morning alert aurinia pharmaceuticals lifts  leads biotechnology sector higher  june   edt june    •  news bites canadian markets  buying and selling insider buying and selling aurinia pharmaceuticals tsxaup director charles a rowland bought  shares worth cad on january  the purchase price  aurinia pharmaceuticals outperforms  of the market may    edt may    •  news bites canadian markets  buying and selling insider buying and selling aurinia pharmaceuticals tsxaup director charles a rowland bought  shares worth cad on january  the purchase price  morning alert aurinia pharmaceuticals drops   underperforming  of stocks  may   edt may    •  news bites canadian markets  buying and selling insider buying and selling aurinia pharmaceuticals tsxaup director charles a rowland bought  shares worth cad on january  the purchase price  threebagger aurinia pharmaceuticals increases may    edt may    •  news bites canadian markets  buying and selling insider buying and selling aurinia pharmaceuticals tsxaup director charles a rowland bought  shares worth cad on january  the purchase price  threebagger aurinia pharmaceuticals increases may    edt may    •  news bites canadian markets  buying and selling insider buying and selling aurinia pharmaceuticals tsxaup director charles a rowland bought  shares worth cad on january  the purchase price  aurinia pharmaceuticals falls for a third consecutive day a threeday fall of  may    edt may    •  news bites canadian markets  buying and selling insider buying and selling aurinia pharmaceuticals tsxaup director charles a rowland bought  shares worth cad on january  the purchase price  twobagger aurinia pharmaceuticals climbs  on robust volume may    edt may    •  news bites canadian markets  buying and selling insider buying and selling aurinia pharmaceuticals tsxaup director charles a rowland bought  shares worth cad on january  the purchase price  afternoon alert aurinia pharmaceuticals lifts  leads biotechnology sector higher  april   edt april    •  news bites canadian markets  buying and selling insider buying and selling aurinia pharmaceuticals tsxaup director charles a rowland bought  shares worth cad on january  the purchase price  aurinia pharmaceuticals keeps sliding down  in  days april    edt april    •  news bites canadian markets  buying and selling insider buying and selling aurinia pharmaceuticals tsxaup director charles a rowland bought  shares worth cad on january  the purchase price  aurinia pharmaceuticals in its biggest weekly gain in  month april    edt april    •  news bites canadian markets  buying and selling insider buying and selling aurinia pharmaceuticals tsxaup director charles a rowland bought  shares worth cad on january  the purchase price  aurinia pharmaceuticals jumps  on strong volume april    edt april    •  news bites canadian markets  buying and selling insider buying and selling aurinia pharmaceuticals tsxaup director charles a rowland bought  shares worth cad on january  the purchase price  aurinia pharmaceuticals sinks  tumbles  for week april    edt april    •  news bites canadian markets  buying and selling insider buying and selling aurinia pharmaceuticals tsxaup director charles a rowland bought  shares worth cad on january  the purchase price  morning alert aurinia pharmaceuticals plummets  leads biotechnology sector lower  march   edt march    •  news bites canadian markets  buying and selling insider buying and selling aurinia pharmaceuticals tsxaup director charles a rowland bought  shares worth cad on january  the purchase price  morning alert aurinia pharmaceuticals down  in  days  march   edt march    •  news bites canadian markets  buying and selling insider buying and selling aurinia pharmaceuticals tsxaup director charles a rowland bought  shares worth cad on january  the purchase price  related news feeds aurinia pharmaceuticals inc biotechnology board and executive moves in biotechnology alumni of saint josephs university email linkedin facebook google tweet reddit permalink want to see the full history of news or view news on a particular date upgrade to relsci professional now start my free trial ➤ industry select a topic keyword go  ➤ find an organization select a topic keyword go  ➤ find a person select a topic keyword go  ➤ name of a school or name of an organization select a topic keyword go  ➤ thank you you are now subscribedplease wait for the page to refresh you are now subscribed to this feed you have unsubscribed to this feed thank you you can now subscribe to more relsci news feeds to subscribe to more than one feed please enter a password please confirm your password go  ➤ youve found a premium relsci pro feature follow news on your contacts upgrade to relsci pro now to easily sync your contacts and stay in the know on the news about the people important to you start my free trial ➤ still not convinced check out our full listing of features here not now youve found a premium relsci pro feature search news on keywords curate your news even further with the ability to filter feeds based on specific keywords mentioned in the articles start my free trial ➤ still not convinced check out our full listing of features here not now industries find news on a particular market people find news about people organizations find news about organizations alumni find news on alumni of any org your contacts find news on your contacts free daily alerts sign up for free daily alerts on this feed sign up ➤ by pressing sign up you agree to our terms of use privacy policy and the lexisnexis terms  conditions already have an account click here to login are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤ viking therapeutics appoints charles a rowland jr to board of directorshomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets close in  hrs  minssp  dow  viking therapeutics appoints charles a rowland jr to board of directorspr newswirejuly  reblogsharetweetsharesan diego july   prnewswire  viking therapeutics inc viking vktx a clinicalstage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders today announced the appointment of charles a rowland jr to its board of directors with more than  years of biopharmaceutical industry experience mr rowland provides viking with broad expertise spanning financial management and strategic business operationscurrently a board member and strategic advisor for multiple biotechnology companies mr rowland was most recently the president and chief executive officer ceo of aurinia pharmaceuticals a clinical stage pharmaceutical company focused on the global lupus nephritis market prior to his tenure with aurinia pharmaceuticals he served as the vice president and chief financial officer cfo of viropharma during which time the company grew into a global biopharmaceutical business with  million in annual revenues until it was acquired by shire plc for  billion before joining viropharma mr rowland was executive vice president and cfo as well as interim coceo for endo pharmaceuticals a specialty pharmaceutical company with  billion in revenues he previously held finance and operational positions of increasing responsibility at biovail pharmaceuticals breakaway technologies pharmacia novartis and bristolmyers squibbwe are fortunate to add an individual with mr rowlands extensive experience and track record to our board of directors  he has made important contributions to multiple successful drug development and commercialization companies as both a senior executive and board member said brian lian phd ceo of viking with our clinical pipeline advancing toward key data readouts and continued progress with our earlier stage programs this is an ideal time to supplement our board with another experienced wellregarded industry voice  we welcome mr rowland and look forward to his contributions to the success of viking therapeutics  mr rowland currently serves as a member of the board of directors for blueprint medicines and nabriva therapeutics with previous board appointments including vitae pharmaceuticals bind therapeutics aurinia pharmaceuticals and idenix pharmaceuticals among others  he holds an mba from rutgers university and a bs from saint josephs universityabout viking therapeutics inc viking therapeutics inc is a clinicalstage biopharmaceutical company focused on the development of novel firstinclass or bestinclass therapies for metabolic and endocrine disorders  the companys research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients lives  viking has exclusive worldwide rights to a portfolio of five therapeutic programs in clinical trials or preclinical studies which are based on small molecules licensed from ligand pharmaceuticals incorporated  the companys clinical programs include vk an orally available nonsteroidal selective androgen receptor modulator or sarm in phase  development for the treatment and prevention of lean body mass loss in patients who have undergone hip fracture surgery vk a small molecule thyroid beta agonist in phase  development for hypercholesterolemia and fatty liver disease and vk a firstinclass orally available drug candidate in phase  development for type  diabetes  viking is also developing novel and selective agonists of the thyroid beta receptor for gsd ia and xlinked adrenoleukodystrophy as well as two earlierstage programs targeting metabolic diseases and anemiafollow viking on twitter vikingvktxforwardlooking statementsthis press release contains forwardlooking statements regarding viking therapeutics including statements about vikings expectations regarding its development activities timelines and milestones as well as the companys goals and plans regarding its clinical and preclinical prospects forwardlooking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance these risks and uncertainties include but are not limited to risks associated with the success cost and timing of vikings product candidate development activities and clinical trials risks that prior clinical and preclinical results may not be replicated and risks regarding regulatory requirements among others these forwardlooking statements speak only as of the date hereof  viking disclaims any obligation to update these forwardlooking statementsread more to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesvikingtherapeuticsappointscharlesarowlandjrtoboardofdirectorshtmlreblogsharetweetsharerecently viewedyour list is emptywhat to read nextshkreli portrayed both as liar wellmeaning as trial nears endreutersengineer finds pattern makes millions in stocksmoney morningsponsoredlife on mars nasa has been testing martian soil for decades to no avail but keeps tryingnewsweekpharma bro wont stop talking except to jury in trialassociated presstrump’s unwitting legacy could be universal health coverageyahoo financetrunk club making sense of styletrunk clubsponsoredsean hannity responds to claim he ran up a  tab at trumps hotel after flying in a yearold lobster from mainebusiness insiderus economic growth picks up in second quarter wages continue to lagreuterstwitter is only famous now because of president trump nyse traderyahoo finance videozuckerberg wifes ambitious secret finally exposedunewzmesponsored ways to break free from your credit card debtyahoo financewall street opens lower as amazon weighs on tech stocksreutersmattis was on vacation when trump tweeted transgender ban and he was reportedly appalled by itbusiness insiderdiscover it  out of  avg by k customersdiscover cardsponsoredstarbucks ceo the amazonwhole foods deal shows where retail is goingyahoo financeamazon could be the first trillion dollar company nyse traderyahoo finance videotrump rages at republicans as john mccain kills obamacare repeal billsuzy q trump promised he had a healthcare bill that would lower costs expand coverage and offer more choices where is his bill time to put up or shut upjoin the conversation   viking therapeutics appoints charles a rowland jr to board of directors viking therapeutics appoints charles a rowland jr to board of directors news provided by viking therapeutics inc jul    et share this article san diego july   prnewswire  viking therapeutics inc viking nasdaq vktx a clinicalstage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders today announced the appointment of charles a rowland jr to its board of directors with more than  years of biopharmaceutical industry experience mr rowland provides viking with broad expertise spanning financial management and strategic business operations currently a board member and strategic advisor for multiple biotechnology companies mr rowland was most recently the president and chief executive officer ceo of aurinia pharmaceuticals a clinical stage pharmaceutical company focused on the global lupus nephritis market prior to his tenure with aurinia pharmaceuticals he served as the vice president and chief financial officer cfo of viropharma during which time the company grew into a global biopharmaceutical business with  million in annual revenues until it was acquired by shire plc for  billion before joining viropharma mr rowland was executive vice president and cfo as well as interim coceo for endo pharmaceuticals a specialty pharmaceutical company with  billion in revenues he previously held finance and operational positions of increasing responsibility at biovail pharmaceuticals breakaway technologies pharmacia novartis and bristolmyers squibb we are fortunate to add an individual with mr rowlands extensive experience and track record to our board of directors  he has made important contributions to multiple successful drug development and commercialization companies as both a senior executive and board member said brian lian phd ceo of viking with our clinical pipeline advancing toward key data readouts and continued progress with our earlier stage programs this is an ideal time to supplement our board with another experienced wellregarded industry voice  we welcome mr rowland and look forward to his contributions to the success of viking therapeutics   mr rowland currently serves as a member of the board of directors for blueprint medicines and nabriva therapeutics with previous board appointments including vitae pharmaceuticals bind therapeutics aurinia pharmaceuticals and idenix pharmaceuticals among others  he holds an mba from rutgers university and a bs from saint josephs university about viking therapeutics inc viking therapeutics inc is a clinicalstage biopharmaceutical company focused on the development of novel firstinclass or bestinclass therapies for metabolic and endocrine disorders  the companys research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients lives  viking has exclusive worldwide rights to a portfolio of five therapeutic programs in clinical trials or preclinical studies which are based on small molecules licensed from ligand pharmaceuticals incorporated  the companys clinical programs include vk an orally available nonsteroidal selective androgen receptor modulator or sarm in phase  development for the treatment and prevention of lean body mass loss in patients who have undergone hip fracture surgery vk a small molecule thyroid beta agonist in phase  development for hypercholesterolemia and fatty liver disease and vk a firstinclass orally available drug candidate in phase  development for type  diabetes  viking is also developing novel and selective agonists of the thyroid beta receptor for gsd ia and xlinked adrenoleukodystrophy as well as two earlierstage programs targeting metabolic diseases and anemia follow viking on twitter vikingvktx forwardlooking statementsthis press release contains forwardlooking statements regarding viking therapeutics including statements about vikings expectations regarding its development activities timelines and milestones as well as the companys goals and plans regarding its clinical and preclinical prospects forwardlooking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance these risks and uncertainties include but are not limited to risks associated with the success cost and timing of vikings product candidate development activities and clinical trials risks that prior clinical and preclinical results may not be replicated and risks regarding regulatory requirements among others these forwardlooking statements speak only as of the date hereof  viking disclaims any obligation to update these forwardlooking statements   to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesvikingtherapeuticsappointscharlesarowlandjrtoboardofdirectorshtml source viking therapeutics inc related links httpwwwvikingtherapeuticscom jul    et preview viking therapeutics completes enrollment in phase  study of vk in patients recovering from hip fracture jun    et preview viking therapeutics announces  million registered direct offering my news release contains wide tables view fullscreen also from this source jul    et viking therapeutics completes enrollment in phase  study of jun    et viking therapeutics announces  million registered direct explore more news releases in similar topics biotechnology health care  hospitals pharmaceuticals personnel announcements you just read viking therapeutics appoints charles a rowland jr to board of directors news provided by viking therapeutics inc jul    et share this article looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search viking therapeutics appoints charles a rowland jr to board of directors  the business journals menu select a city national albany albuquerque atlanta austin baltimore birmingham boston buffalo charlotte chicago cincinnati columbus dallas dayton denver greensborowinstonsalem honolulu houston jacksonville kansas city los angeles louisville memphis miamifort lauderdale milwaukee minneapolisst paul nashville new york orlando philadelphia phoenix pittsburgh portland raleighdurham sacramento san antonio san francisco seattle silicon valley st louis tampa bay washington dc wichita limited time offer subscribe now search × close sign in sign in your account your account welcome your account sign in existing users create your free account dont have an account your account subscriptions newsletters custom notifications my custom site manage site users sign out sign in sign in your account search home industries  topics all industries  topics banking  financial services career  workplace commercial real estate education energy food  lifestyle government  regulations health care manufacturing media  marketing philanthropy  nonprofits professional services residential real estate retailing sports business technology transportation travel  tourism sponsored content cre now we value your business office environments small business marketing know your neighborhood news news latest news business pulse press releases lists  awards lists all lists build your own lists people  companies companies top private companies find businesses for sale search for company news people people on the move contact top executives executive profiles search for people in the news events events business event calendar nominations more… jobs find or post a job store subscriptions reprints  more how to grow your business advance your career thought leadership trends tips and insights from our partners subscribers manage your account about  contact about the business journals advertise help  faqs call center directory apps  syndication newsletters acbj publications bizwomen upstart hemmings sports business journal inside lacrosse bostinno dcinno chicagoinno austininno select a city national albany albuquerque atlanta austin baltimore birmingham boston buffalo charlotte chicago cincinnati columbus dallas dayton denver greensborowinstonsalem honolulu houston jacksonville kansas city los angeles louisville memphis miamifort lauderdale milwaukee minneapolisst paul nashville new york orlando philadelphia phoenix pittsburgh portland raleighdurham sacramento san antonio san francisco seattle silicon valley st louis tampa bay washington dc wichita follow us twitter linkedin facebook google  press releases viking therapeutics appoints charles a rowland jr to board of directors jul   am edt san diego july   prnewswire  viking therapeutics inc viking nasdaq vktx a clinicalstage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders today announced the appointment of charles a rowland jr to its board of directors with more than  years of biopharmaceutical industry experience mr rowland provides viking with broad expertise spanning financial management and strategic business operations currently a board member and strategic advisor for multiple biotechnology companies mr rowland was most recently the president and chief executive officer ceo of aurinia pharmaceuticals a clinical stage pharmaceutical company focused on the global lupus nephritis market prior to his tenure with aurinia pharmaceuticals he served as the vice president and chief financial officer cfo of viropharma during which time the company grew into a global biopharmaceutical business with  million in annual revenues until it was acquired by shire plc for  billion before joining viropharma mr rowland was executive vice president and cfo as well as interim coceo for endo pharmaceuticals a specialty pharmaceutical company with  billion in revenues he previously held finance and operational positions of increasing responsibility at biovail pharmaceuticals breakaway technologies pharmacia novartis and bristolmyers squibb we are fortunate to add an individual with mr rowlands extensive experience and track record to our board of directors  he has made important contributions to multiple successful drug development and commercialization companies as both a senior executive and board member said brian lian phd ceo of viking with our clinical pipeline advancing toward key data readouts and continued progress with our earlier stage programs this is an ideal time to supplement our board with another experienced wellregarded industry voice  we welcome mr rowland and look forward to his contributions to the success of viking therapeutics   mr rowland currently serves as a member of the board of directors for blueprint medicines and nabriva therapeutics with previous board appointments including vitae pharmaceuticals bind therapeutics aurinia pharmaceuticals and idenix pharmaceuticals among others  he holds an mba from rutgers university and a bs from saint josephs university about viking therapeutics inc viking therapeutics inc is a clinicalstage biopharmaceutical company focused on the development of novel firstinclass or bestinclass therapies for metabolic and endocrine disorders  the companys research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients lives  viking has exclusive worldwide rights to a portfolio of five therapeutic programs in clinical trials or preclinical studies which are based on small molecules licensed from ligand pharmaceuticals incorporated  the companys clinical programs include vk an orally available nonsteroidal selective androgen receptor modulator or sarm in phase  development for the treatment and prevention of lean body mass loss in patients who have undergone hip fracture surgery vk a small molecule thyroid beta agonist in phase  development for hypercholesterolemia and fatty liver disease and vk a firstinclass orally available drug candidate in phase  development for type  diabetes  viking is also developing novel and selective agonists of the thyroid beta receptor for gsd ia and xlinked adrenoleukodystrophy as well as two earlierstage programs targeting metabolic diseases and anemia follow viking on twitter vikingvktx forwardlooking statementsthis press release contains forwardlooking statements regarding viking therapeutics including statements about vikings expectations regarding its development activities timelines and milestones as well as the companys goals and plans regarding its clinical and preclinical prospects forwardlooking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance these risks and uncertainties include but are not limited to risks associated with the success cost and timing of vikings product candidate development activities and clinical trials risks that prior clinical and preclinical results may not be replicated and risks regarding regulatory requirements among others these forwardlooking statements speak only as of the date hereof  viking disclaims any obligation to update these forwardlooking statements   to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesvikingtherapeuticsappointscharlesarowlandjrtoboardofdirectorshtml source viking therapeutics inc the information on this page is provided by pr newswire all rights reserved reproduction or redistribution of this content without prior written consent from pr newswire is strictly prohibited is not responsible for this content learn more about this service about pr newswire the information on this page is provided by pr newswire the business journals is not responsible for this content learn more